These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3330095)

  • 1. The effect of TP-3 (Arg-Lys-Asp), TP-4 (Arg-Lys-Asp-Val), and TP-5 on the metastatic capacity of intravenously injected Lewis lung tumor cells.
    Szende B; Lapis K; Pal K; Sipos L; Denes L; Kisfaludy L
    Immunopharmacol Immunotoxicol; 1987; 9(1):19-24. PubMed ID: 3330095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of TP-5 and its analogs on skin grafts in mice.
    Szende B; Kisfaludy L; Lapis K; Dénes L; Szporny L; Nyéke O; Schön I; Hajós G; Ember J; Constantin M
    J Immunopharmacol; 1985; 7(1):67-78. PubMed ID: 3891868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic possibilities of thymopoietin fragments (TP3 and TP4) based on experimental animal models.
    Dénes L; Szende B; Hajós G; Szporny L; Lapis K
    Drugs Exp Clin Res; 1987; 13(5):279-87. PubMed ID: 3500029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoregulating peptides II. In vitro effects of TP5 analogs on E-rosette formation and cell division.
    Denes L; Szende B; Ember J; Major J; Szporny L; Hajos G; Nyeki O; Schon I; Lapis K; Kisfaludy L
    Immunopharmacol Immunotoxicol; 1987; 9(1):1-18. PubMed ID: 3330094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymopoietin pentapeptide (thymopentin, TP-5) in the treatment of rheumatoid arthritis. A compilation of several short- and longterm clinical studies.
    Veys EM; Mielants H; Verbruggen G; Spiro T; Newdeck E; Power D; Goldstein G
    J Rheumatol; 1984 Aug; 11(4):462-6. PubMed ID: 6384507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies of thymopoietin pentapeptide (TP5) on experimental tumors. I. TP5 relieves immunosuppression in tumor-bearing mice.
    Lau CY; Wang EY; Goldstein G
    Cell Immunol; 1982 Jan; 66(2):217-32. PubMed ID: 6802504
    [No Abstract]   [Full Text] [Related]  

  • 7. Further investigations on thymopentin-like fragments of HLA-DQ and their analogs.
    Szewczuk Z; Wieczorek Z; Stefanowicz P; Wilczyński A; Siemion IZ
    Arch Immunol Ther Exp (Warsz); 1997; 45(4):335-41. PubMed ID: 9523010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of cutaneous T-cell lymphomas with TP-5. Evaluation of the clinical effect in 8 patients.
    Przybilla B; Burg G; Schmoeckel C; Braun-Falco O
    Acta Derm Venereol; 1983; 63(6):524-9. PubMed ID: 6198843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the metastasis of murine malignant melanoma by synthetic polymeric peptides containing core sequences of cell-adhesive molecules.
    Saiki I; Iida J; Murata J; Ogawa R; Nishi N; Sugimura K; Tokura S; Azuma I
    Cancer Res; 1989 Jul; 49(14):3815-22. PubMed ID: 2736523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymopentin (TP-5) in the treatment of the postburn and postoperative immunodeficiency syndrome.
    Hamilton G; Zöch G; Rath T; Meissl G
    Prog Clin Biol Res; 1989; 308():995-9. PubMed ID: 2528748
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapy with thymopoietin pentapeptide (TP-5) in 26 patients with primary immunodeficiencies.
    Aiuti F; Businco L; Fiorilli M; Galli E; Quinti I; Le Moli S; Seminara R; Goldstein G
    Birth Defects Orig Artic Ser; 1983; 19(3):267-72. PubMed ID: 6360238
    [No Abstract]   [Full Text] [Related]  

  • 12. [Conformation states of thymopentin and its synthetic analogs].
    Akhmedov NA; Khalilova NM; Popov EM
    Mol Biol (Mosk); 1987; 21(1):159-63. PubMed ID: 3553894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of natural killer activity and of T cells after thymopoietin pentapeptide therapy in a patient with severe combined immunodeficiency.
    Fiorilli M; Sirianni MC; Pandolfi F; Quinti I; Tosti U; Aiuti F; Goldstein G
    Clin Exp Immunol; 1981 Aug; 45(2):344-51. PubMed ID: 7032772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymopoietin to thymopentin: experimental studies.
    Goldstein G; Audhya TK
    Surv Immunol Res; 1985; 4 Suppl 1():1-10. PubMed ID: 2994196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymic humoral factor-gamma 2 (THF-gamma 2) immunotherapy reduces the metastatic load and restores immunocompetence in 3LL tumor-bearing mice receiving anticancer chemotherapy.
    Ophir R; Pecht M; Keisari Y; Rashid G; Lourie S; Meshorer A; Ben-Efraim S; Trainin N; Burstein Y
    Immunopharmacol Immunotoxicol; 1996 May; 18(2):209-36. PubMed ID: 8771368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of Di George syndrome treated with thymopoietin pentapeptide (TP-5) demonstrating an adherent suppressor cell of lymphocyte function.
    Joffe MI; Sochett E; Pettifor JM; Rabson AR
    J Clin Lab Immunol; 1982 May; 8(1):69-73. PubMed ID: 6212686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymopentin in the treatment of alopecia areata.
    Orecchia G
    Dermatologica; 1989; 178(4):231. PubMed ID: 2670621
    [No Abstract]   [Full Text] [Related]  

  • 18. Thymopentin and splenopentin as immunomodulators. Current status.
    Singh VK; Biswas S; Mathur KB; Haq W; Garg SK; Agarwal SS
    Immunol Res; 1998; 17(3):345-68. PubMed ID: 9638477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stimulation of cellular function by thymopentin (TP-5) in three AIDS patients.
    Mascart-Lemone F; Huygen K; Clumeck N; Brenez D; Bolla K; Duchateau J
    Lancet; 1983 Sep; 2(8352):735-6. PubMed ID: 6193382
    [No Abstract]   [Full Text] [Related]  

  • 20. [Treatment of recurrent herpes simplex with thymopoietin-pentapeptide].
    Djawari D; Bolla K; Haneke E
    Dtsch Med Wochenschr; 1984 Mar; 109(13):496-8. PubMed ID: 6368167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.